MINDY DEGEUS: Open Payments
NPI 1316589278 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 60 payments from 12 companies in 2025. Trend: 2023 $699 · 2024 $1,065 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $330 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $140 |
| AstraZeneca Pharmaceuticals LP | 3 | $136 |
| Antares Pharma, Inc. | 3 | $84 |
| PFIZER INC. | 4 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| Novo Nordisk Inc | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $33 |
Products named: CAPLYTA, AIRSUPRA, UBRELVY, QULIPTA, VRAYLAR, XYOSTED, NURTEC ODT, REXULTI.
Industry payments across ID — which companies pay providers there.
